secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-06-29T11:06:42+00:00
Accession:  0001171843-26-004333
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst shuts internal discovery, closes Birmingham facility; navenibart Phase 3 enrollment complete; guidance improved
--------------------------------------------------------------------------------

- Board approved discontinuation of internal discovery programs and closure of Birmingham, AL facility by end 2026.
- Phase 3 ALPHA-ORBIT for navenibart (HAE) enrollment completed; top-line data expected Q3 2027.
- Resolved manufacturing delay for ORLADEYO oral pellets; product available early August 2026.
- 2026 non-GAAP operating expense guidance lowered to $420-440M from $450-470M; revenue guidance reaffirmed at $635-660M.
- BCX17725 (Netherton syndrome) Phase 1 Part 4 dosing ongoing; proof-of-concept data expected year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/0001171843-26-004333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/f8k_062926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer